Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gambro subpoenaed on PTH testing

This article was originally published in The Gray Sheet

Executive Summary

Despite receipt of a Nov. 5 DoJ subpoena seeking documentation on parathyroid hormone testing, Gambro remains on-track to finalize by year-end a July preliminary settlement agreement with the U.S. Department of Justice related to renal care Medicare billing practices initially cited in a June 2001 subpoena, the firm says (1"The Gray Sheet" July 26, 2004, p. 13). Similar subpoenas on PTH testing were received the week of Oct. 25 by several other dialysis-related product and service providers as part of an industry-wide investigation aimed at increasing DoJ's understanding of PTH testing and vitamin D therapy (2"The Gray Sheet" Nov. 1, 2004, In Brief). PTH testing represents about 1% of total U.S. Gambro Healthcare revenue...

You may also be interested in...

Gambro Settles Medicare Billing Suit, Signs Corporate Integrity Agreement

Gambro Healthcare US will record a second quarter charge of $355 mil. to cover a definitive settlement agreement with the U.S. Department of Justice, expected to be completed by December

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts